drug
fosdenopterin hydrobromide
Marketedupdated 3mo agoby Sentynl Therapeutics Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 26, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Apr 9, 2029formulationUS 75040952.6y
FDA exclusivities (2)
- Feb 26, 2028ODE-342Orphan Drug (7y)1.5y
- Feb 26, 2026NCENew Chemical Entity (5y)
News(1)
- Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drugSentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.fiercebiotech · 6d ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that